AGL US Earnings call
agilon health, inc. (AGL) · Q2 2026 results
Share price: $114.81 · 2026-11-11
Results Q2 2026 vs Q1 2026 · previous quarter · published 5 Aug 2026 and 6 May 2026
Net income down 63.3% on the previous quarter, guidance raised. Management sounded about as positive as a typical company call, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
−63.3%
Net income vs Q1 2026
Guidance raised
Net income 18.0M vs 48.9M
Revenue +5.2%
2 · How management spoke
Typical
Less upbeat than 60% of company calls
Answers to analysts: restrained, in line with the script.
Similar to last call.
3 · What stood out
Figure
AGL said its program improved inpatient first diagnosis rates within its network, signaling the initiative is working.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$114.81
close of 2026-11-11
Revenue growth, 3 years
+35.4% a year
compound annual rate (CAGR)
Free cash flow 2023
−$0.2B
Free cash flow 2024
−$0.1B
Free cash flow 2025
−$0.1B
Read between the lines
-
Guidance
AGL now expects full year 2026 revenue of approximately $5.8 billion, updating guidance to clarify its annual sales outlook.
Source quote
“Using the midpoint of our guidance ranges for the full year 2026, we now expect revenue of approximately $5.8 billion, medical margin of approximately $485 million, and adjusted...”
-
Guidance ↑
AGL raised its full-year 2026 guidance because of year-to-date performance and an assumed cost trend in a 7% range for the remainder of the year.
Source quote
“The increased full-year 2026 guidance reflects the year-to-date performance, prudent assumption for cost trends in a 7% range for the remainder of the year, and the positive impact...”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“Our focus for both programs is on earlier identification, expanded screenings, and increased utilization of advanced diagnostics by our physician groups, each of which is designed to drive earlier intervention,...”
“With advances in our enhanced data pipeline, we continue to gain earlier insights to further improve both operational execution and support our PCP partners to drive improved patient outcomes through...”
“Our performance in the second quarter, the improved medical cost trend we began to see in the first quarter, and a stronger-than-expected performance of our Burden of Illness program that...”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Metric | Q2 2026period end 2026-06-30 | Q1 2026period end 2026-03-31 | Change | Q2 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 1.49B | 1.42B | +5.2% | 1.39B | +7.2% |
| Operating income | 11.8M | 4.0M | +194.5% | -116.0M | Turned profit |
| Net income | 18.0M | 48.9M | −63.3% | -104.4M | Turned profit |
| EPS | 1.04 | 2.94 | −64.6% | -6.31 | Turned profit |
| P/E | — | — | — | — | — |
Topics
Most discussed now
- To further agilon health's mission, Agilon continues to advance new clinical, quality, and AI initiatives that will build upon its…
- I am listening, learning, and focusing on key areas to drive additional value for all of agilon health's stakeholders.
- This, combined with agilon health's enhanced data visibility and estimation process, provide confidence in the underlying performance of…
- The positive results and increase to agilon health's full year guidance were driven by better-than-expected performance in the diagnosis…
- As a reminder, a subset of agilon health's Medicare Advantage members remain in care coordination fee arrangements.
Faded since Q1 2026
- Dropped I will provide an update on cost and macroeconomic trends, including the recently announced final rate notice for 2027.
- Dropped The other thing is capture corridors or carving out things that are outside of agilon health's control like supplemental benefits.
- Fading Its performance demonstrates operational discipline, the strength of its long-term physician partnerships, and early benefits from the…
- Fading Tim brings significant experience across the payer and provider space with a deep understanding of what is needed to succeed...
Latest announcements
Official filings, newest first.
- Results of operations · SEC 8-K
- Director or officer change · SEC 8-K
- Shareholder vote results · SEC 8-K
- Results of operations · SEC 8-K
- Director or officer change; Regulation FD disclosure · SEC 8-K
- Change to shareholder rights; Articles or bylaws amended · SEC 8-K
- Shareholder vote results; Other events · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K